Photo: CNBC
Business & Finance
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
TL;DR
- Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Nov 3, 2026 · Updated 11/3/2026, 11:19:21 AM · Reported with: CNBC
Sources (1)
NRI Bytes writes its own articles from the reporting below.
CNBC — A little-known biotech’s high-stakes cancer bet just paid off and its shares doubledUp next · Business & Finance
US Midterm Elections: Kalyan Jewellers, PC, Lalithaa to Senco; top jewellery stock to buy as gold, silver rates rebound
Read next →
More stories
Business & Finance
Nagaland govt says ‘credentials shared via Aadhaar app to be a valid proof of identity’ | All you need to know
45m ago
Business & Finance
BMW Q3 profit falls 15% as China competition weighs
45m ago
Business & Finance
12 BSE 500 stocks defy market trend, rally up to 65% in 3 months
1h ago
Business & Finance
Cabinet clears ₹14,500 crore energy storage plan
6m ago·2 sources
